Reassessing the two-year rodent carcinogenicity bioassay: a review of the applicability to human risk and current perspectives.
暂无分享,去创建一个
A. Hayes | P. Marone | William C Hall | Palma Ann Marone | A Wallace Hayes | W. Hall | William C. Hall | A. Wallace Hayes
[1] A. Kinsella,et al. Long Term and Short Term Screening Assays for Carcinogens: A Critical Appraisal , 1981, British Journal of Cancer.
[2] L. Gold,et al. Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature in 1993 to 1994 and by the National Toxicology Program in 1995 to 1996. , 1999, Environmental health perspectives.
[3] N. Page,et al. Guidelines for carcinogen bioassay in small rodents. , 1976, National Cancer Institute carcinogenesis technical report series.
[4] John D. Walker,et al. Use of QSARs in international decision-making frameworks to predict health effects of chemical substances. , 2003, Environmental health perspectives.
[5] W. Fritz. WHO‐IARC Monographs on the evaluation of carcinogenic risk of chemicals to humans. Supplement 2: Long‐Term and Short‐Term Screening Assays for carcinogens: A critical appraisal. 426 Seiten. International Agency for Research on Cancer, Lyon 1980. Preis: 40,‐sfrs.; 25,‐US$ , 1982 .
[6] J A Heddle,et al. A rapid in vivo test for chromosomal damage. , 1973, Mutation research.
[7] E. Benfenati,et al. A combination of 3D-QSAR, docking, local-binding energy (LBE) and GRID study of the species differences in the carcinogenicity of benzene derivatives chemicals. , 2008, Journal of molecular graphics & modelling.
[8] Ran Kivetz,et al. Alternative Models for Capturing the Compromise Effect , 2004 .
[9] Alessandro Giuliani,et al. Alternatives to the carcinogenicity bioassay: in silico methods, and the in vitro and in vivo mutagenicity assays , 2010, Expert opinion on drug metabolism & toxicology.
[10] C. Portier,et al. Optimal design of the chronic animal bioassay. , 1983, Journal of toxicology and environmental health.
[11] Chien-Jen Chen,et al. Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B– and C–related risk , 2003, Hepatology.
[12] D. Dix,et al. The ToxCast program for prioritizing toxicity testing of environmental chemicals. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[13] J. Contrera,et al. In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals. , 1998, Environmental health perspectives.
[14] National Library of Medicine and Its Toxicology and Environmental Health Information Program , 2014 .
[15] J. Ward. The Roles of the Toxicologic Pathologist in Cancer Research , 2010, Toxicologic pathology.
[16] Hugo M Vargas,et al. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals , 2013, Expert opinion on drug safety.
[17] G. Williams,et al. Short- and intermediate-term carcinogenicity testing--a review. Part 2: available experimental models. , 1998, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[18] D. B. McGregor,et al. The use of short-and medium-term tests for carcinogens and data on genetic effects in carcinogenic hazard evaluation. Consensus report. , 1999, IARC scientific publications.
[19] R. Tamura,et al. Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys. , 1991, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[20] C. Thompson,et al. Application of the U.S. EPA Mode of Action Framework for Purposes of Guiding Future Research: A Case Study Involving the Oral Carcinogenicity of Hexavalent Chromium , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[21] S. Orsulic,et al. Mouse models of cancer. , 2011, Annual review of pathology.
[22] Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. , 1987, IARC monographs on the evaluation of carcinogenic risks to humans. Supplement.
[23] R. Tennant,et al. The use of transgenic animals in cancer testing. , 1999, Inhalation toxicology.
[24] M. Waters,et al. Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods. , 2010, Mutation research.
[25] D. Rall. LABORATORY ANIMAL TESTS AND HUMAN CANCER* , 2000, Drug metabolism reviews.
[26] S. Cohen. Evaluation of Possible Carcinogenic Risk to Humans Based on Liver Tumors in Rodent Assays , 2010, Toxicologic pathology.
[27] J. Bucher. The National Toxicology Program Rodent Bioassay , 2002 .
[28] M. Soffritti,et al. Ramazzini Foundation Cancer Program , 2002, Annals of the New York Academy of Sciences.
[29] D. Gaylor,et al. Experimental design of bioassays for screening and low dose extrapolation. , 1985, Risk Analysis.
[30] C. Alden,et al. The Tg rasH2 Mouse in Cancer Hazard Identification , 2002, Toxicologic pathology.
[31] G Pearse,et al. Prediction of Rodent Carcinogenesis: An Evaluation of Prechronic Liver Lesions as Forecasters of Liver Tumors in NTP Carcinogenicity Studies , 2004, Toxicologic pathology.
[32] J. Haseman,et al. The relationship between use of the maximum tolerated dose and study sensitivity for detecting rodent carcinogenicity. , 1994, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[33] J. Haseman,et al. The Relationship between Use of the Maximum Tolerated Dose and Study Sensitivity for Detecting Rodent Carcinogenicity , 1994 .
[34] S. O’Rahilly,et al. PPAR gamma and human metabolic disease. , 2006, The Journal of clinical investigation.
[35] John D. Walker,et al. Global Government applications of analogues, SAR s and QSAR s to predict aquatic toxicity, chemical or physical properties, environmental fate parameters and health effects of organic chemicals , 2002, SAR and QSAR in environmental research.
[36] J. Weisburger. Carcinogenicity and mutagenicity testing, then and now. , 1999, Mutation research.
[37] F. Belpoggi,et al. The Scientific and Methodological Bases of Experimental Studies for Detecting and Quantifying Carcinogenic Risks , 1999, Annals of the New York Academy of Sciences.
[38] M. V. von Wittenau,et al. Cancer risk assessment , 1995, Science.
[39] W Schmid,et al. The micronucleus test. , 1975, Mutation research.
[40] Gbo,et al. Prediction of carcinogenic potential of substances using repeated dose toxicity data , 2012 .
[41] R. Ponce,et al. Carcinogenicity Assessments of Biotechnology-Derived Pharmaceuticals , 2010, Toxicologic pathology.
[42] D. Freedman,et al. Concordance between rats and mice in bioassays for carcinogenesis. , 1996, Regulatory toxicology and pharmacology : RTP.
[43] B. Ames,et al. An improved bacterial test system for the detection and classification of mutagens and carcinogens. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[44] Mary J. C. Hendrix,et al. Reprogramming metastatic tumour cells with embryonic microenvironments , 2007, Nature Reviews Cancer.
[45] J. French,et al. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[46] R L Kodell,et al. A review of mammalian carcinogenicity study design and potential effects of alternate test procedures on the safety evaluation of food ingredients. , 2011, Regulatory toxicology and pharmacology : RTP.
[47] Emilio Benfenati,et al. The Expanding Role of Predictive Toxicology: An Update on the (Q)SAR Models for Mutagens and Carcinogens , 2007, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.
[48] K Yamagiwa,et al. Experimental study of the pathogenesis of carcinoma , 1977, CA: a cancer journal for clinicians.
[49] L. Weisenthal,et al. Clonogenic and nonclonogenic in vitro chemosensitivity assays. , 1985, Cancer treatment reports.
[50] W. Stott,et al. Mechanisms of chemical carcinogenicity , 1989 .
[51] A. Hayes. Principles and methods of toxicology , 1982 .
[52] G. Williams,et al. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. , 1996, Pharmacology & therapeutics.
[53] C. Alden,et al. Improving Carcinogenicity Assessment , 2013, Toxicologic pathology.
[54] U. Epa. Guidelines for carcinogen risk assessment , 1986 .
[55] H. Masuda,et al. Testing for carcinogenicity of pharmaceuticals. , 1996, The Journal of toxicological sciences.
[56] R. Shaw,et al. Calcium phosphate-containing precipitate and the carcinogenicity of sodium salts in rats. , 2000, Carcinogenesis.
[57] R. Parker,et al. Society of Toxicologic Pathology , 2014 .
[58] Melvin E Andersen,et al. Dose-dependent transitions in mechanisms of toxicity: case studies. , 2004, Toxicology and applied pharmacology.
[59] E. Jacoby,et al. Chemogenomics: an emerging strategy for rapid target and drug discovery , 2004, Nature Reviews Genetics.
[60] Alan R. Boobis,et al. IPCS Framework for Analyzing the Relevance of a Cancer Mode of Action for Humans , 2006 .
[61] M. Neel,et al. The Molecular Basis of Human Cancer , 1993 .
[62] Prashant S Khakar. Two-dimensional (2D) in silico models for absorption, distribution, metabolism, excretion and toxicity (ADME/T) in drug discovery. , 2010, Current topics in medicinal chemistry.
[63] A. Giuliani,et al. Exploring In Vitro/In Vivo Correlation: Lessons Learned from Analyzing Phase I Results of the US EPA's ToxCast Project , 2010, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.
[64] H. Murff,et al. Cancer risk assessment: quality and impact of the family history interview. , 2004, American journal of preventive medicine.
[65] F. Sistare,et al. An Evaluation of Chronic 6- and 12-Month Rat Toxicology Studies as Predictors of 2-Year Tumor Outcome , 2010, Veterinary pathology.
[66] A. Aitio,et al. Human Carcinogens So Far Identified , 1989, Japanese journal of cancer research : Gann.
[67] S. Uwagawa,et al. Case study: an evaluation of the human relevance of the synthetic pyrethroid metofluthrin-induced liver tumors in rats based on mode of action. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[68] W. Pao,et al. How genetically engineered mouse tumor models provide insights into human cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] J. Haseman,et al. Evaluation of false positive and false negative outcomes in NTP long-term rodent carcinogenicity studies. , 1996, Risk analysis : an official publication of the Society for Risk Analysis.
[70] R. Ettlin. Toxicologic Pathology in the 21st Century , 2013, Toxicologic pathology.
[71] G. Williams,et al. Short- and intermediate-term carcinogenicity testing--a review. Part 1: the prototypes mouse skin tumour assay and rat liver focus assay. , 1998, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[72] W. Stokes,et al. The international symposium on regulatory testing and animal welfare: recommendations on best scientific practices for subchronic/chronic toxicity and carcinogenicity testing. , 2002, ILAR journal.
[73] J. D. Camargo. Chemical carcinogenesis – mode of action to inform quantitative human risk , 2013 .
[74] A. Monro. Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents? , 1996, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[75] Joy A. Cavagnaro,et al. Preclinical safety evaluation of biotechnology-derived pharmaceuticals , 2002, Nature Reviews Drug Discovery.
[76] Stu Borman. Drug Design On The Fast Track , 2014 .
[77] Rajendra Mehta,et al. Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals , 1996, Journal of cellular biochemistry. Supplement.
[78] Ricardo Macarron,et al. Critical review of the role of HTS in drug discovery. , 2006, Drug discovery today.
[79] P. Infante. Use of rodent carcinogenicity test results for determining potential cancer risk to humans. , 1993, Environmental health perspectives.
[80] L. Sachs,et al. In vitro transformation of normal cells to tumor cells by carcinogenic hydrocarbons. , 1965, Journal of the National Cancer Institute.
[81] J. Ward. The Two-Year Rodent Carcinogenesis Bioassay — Will It Survive? , 2007 .
[82] E. Mcconnell,et al. The Value and Significance of Life Span and Scheduled Termination Data in Long-term Toxicity and Carcinogenesis Studies , 1985, Toxicologic pathology.
[83] Raffaella Corvi,et al. Recommended lists of genotoxic and non-genotoxic chemicals for assessment of the performance of new or improved genotoxicity tests: a follow-up to an ECVAM workshop. , 2008, Mutation research.
[84] C. Austin,et al. Improving the Human Hazard Characterization of Chemicals: A Tox21 Update , 2013, Environmental health perspectives.
[85] S. O’Rahilly,et al. Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance , 2006, Cell metabolism.
[86] R. Maronpot,et al. The Orphan Nuclear Receptor Constitutive Active/Androstane Receptor Is Essential for Liver Tumor Promotion by Phenobarbital in Mice , 2004, Cancer Research.
[87] J. Timbrell,et al. Casarett and Doull's Toxicology: The Basic Science of Poisons , 1981 .
[88] G. Williams,et al. Application of a cellular test battery in the decision point approach to carcinogen identification. , 1988, Mutation research.
[89] M Younes,et al. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. , 2001, Regulatory toxicology and pharmacology : RTP.
[90] James R. Downing,et al. Annual review of pathology : mechanisms of disease , 2006 .
[91] E. Weisburger. Techniques for carcinogenicity studies. , 1981, Cancer research.
[92] D. Jacobson-Kram. Cancer Risk Assessment Approaches at the FDA/CDER: Is the Era of the 2-Year Bioassay Drawing to a Close? , 2010, Toxicologic pathology.
[93] J M Ward,et al. Factors in the evaluation of 200 National Cancer Institute carcinogen bioassays. , 1981, Journal of toxicology and environmental health.
[94] J. Huff,et al. Evolution of Research in Cancer Etiology , 2002 .
[95] C. Bielza,et al. Mouse p53-Deficient Cancer Models as Platforms for Obtaining Genomic Predictors of Human Cancer Clinical Outcomes , 2012, PloS one.
[96] C. Bolognesi,et al. Scientific opinion on genotoxicity testing strategies applicable to food and 3 feed safety assessment , 2011 .
[97] Valérie Zuang,et al. Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010 , 2011, Archives of Toxicology.
[98] M. Fenech,et al. In vitro genotoxicity testing using the micronucleus assay in cell lines, human lymphocytes and 3D human skin models. , 2011, Mutagenesis.
[99] A. J. Lehman,et al. Procedures for the appraisal of the toxicity of chemicals in foods. , 1949, Food, Drug, cosmetic law quarterly.
[100] Romualdo Benigni,et al. Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology. , 2011, Chemical reviews.
[101] S. Plassmann,et al. Successful Drug Development Despite Adverse Preclinical Findings Part 1: Processes to Address Issues and Most Important Findings , 2010, Journal of toxicologic pathology.
[102] Gary M Williams,et al. Application of mode-of-action considerations in human cancer risk assessment. , 2008, Toxicology letters.
[103] J. Miller,et al. The carcinogenic aminoazo dyes. , 1953, Advances in cancer research.
[104] Lutz Müller,et al. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. , 2005, Mutation research.
[105] J. Waldrep,et al. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. , 2010, Anticancer research.
[106] I. Lambert,et al. Detailed review of transgenic rodent mutation assays. , 2005, Mutation research.
[107] A. Jacobs. Prediction of 2-year carcinogenicity study results for pharmaceutical products: how are we doing? , 2005, Toxicological sciences : an official journal of the Society of Toxicology.
[108] S. Cohen. Urinary Bladder Carcinogenesis by DNA Reactive and Non-Reactive Chemicals: Non-Linearities and Thresholds , 2012 .
[109] B. Ames,et al. What do animal cancer tests tell us about human cancer risk?: Overview of analyses of the carcinogenic potency database. , 1998, Drug metabolism reviews.
[110] R. Tennant,et al. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. , 1996, Mutation research.
[111] Robert J Kavlock,et al. Incorporating biological, chemical, and toxicological knowledge into predictive models of toxicity. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[112] G. B. Gori. Regulatory Forum Opinion Piece , 2013, Toxicologic pathology.
[113] J. Taylor,et al. An industry perspective , 2015 .
[114] G. Williams,et al. The distinction between genotoxic and epigenetic carcinogens and implication for cancer risk. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.
[115] Luis G Valerio,et al. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling. , 2007, Toxicology and applied pharmacology.
[116] Andrew P. Worth,et al. The Role of Qsar Methodology in the Regulatory Assessment of Chemicals , 2010 .
[117] Carolyn Vickers,et al. IPCS framework for analysing the relevance of a cancer mode of action for humans , 2006 .
[118] J. Huff,et al. The Limits of Two-Year Bioassay Exposure Regimens for Identifying Chemical Carcinogens , 2008, Environmental health perspectives.
[119] J. Bucher. The National Toxicology Program rodent bioassay: designs, interpretations, and scientific contributions. , 2002, Annals of the New York Academy of Sciences.
[120] M. Long. Predicting carcinogenicity in humans: The need to supplement animal-based toxicology , 2006 .
[121] R B Conolly,et al. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments. , 1995, Cancer letters.
[122] Trevor Green,et al. Case study: weight of evidence evaluation of the human health relevance of thiamethoxam-related mouse liver tumors. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.
[123] David Y. Lai,et al. PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance , 2003 .
[124] Frank D Sistare,et al. Use of Transgenic Mice in Carcinogenicity Hazard Assessment , 2004, Toxicologic pathology.
[125] B. Leblanc,et al. Pathology and Tissue Sampling Protocols for Rodent Carcinogenicity Studies: Time for Revision , 2000, Toxicologic pathology.
[126] R. Tennant,et al. Review Article: Use of Transgenic Animals for Carcinogenicity Testing: Considerations and Implications for Risk Assessment , 2000 .
[127] Inmar E. Givoni,et al. Exploring the Mode-of-Action of Bioactive Compounds by Chemical-Genetic Profiling in Yeast , 2006, Cell.
[128] Vicki L Dellarco,et al. A risk assessment perspective: application of mode of action and human relevance frameworks to the analysis of rodent tumor data. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.
[129] David M. Reif,et al. Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management. , 2012, Chemical research in toxicology.
[130] Ord,et al. Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens , 2013 .
[131] F. D. De Braud,et al. Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer , 2003, Pharmacological Reviews.
[132] C. Alden,et al. A Critical Appraisal of the Value of the Mouse Cancer Bioassay in Safety Assessment , 1996, Toxicologic pathology.
[133] A. Wakata,et al. Safety assessment of biopharmaceuticals: Japanese perspective on ICH S6 guideline maintenance. , 2008, The Journal of toxicological sciences.
[134] David W Gaylor,et al. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens? , 2005, Regulatory toxicology and pharmacology : RTP.
[135] Kathryn Z. Guyton,et al. Mode of Action Frameworks: A Critical Analysis , 2008, Journal of toxicology and environmental health. Part B, Critical reviews.
[136] G. Williams,et al. The decision-point approach for systematic carcinogen testing. , 1981, Food and cosmetics toxicology.
[137] S. Cohen,et al. Alternative models for carcinogenicity testing. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.
[138] Lester B Lave,et al. Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity. , 2003, Regulatory toxicology and pharmacology : RTP.
[139] John R. Bucher,et al. Conflicting Views on Chemical Carcinogenesis Arising from the Design and Evaluation of Rodent Carcinogenicity Studies , 2007, Environmental health perspectives.
[140] Robert J Kavlock,et al. Economic benefits of using adaptive predictive models of reproductive toxicity in the context of a tiered testing program , 2012, Systems biology in reproductive medicine.
[141] R. Storer,et al. An Industry Perspective on the Utility of Short-Term Carcinogenicity Testing in Transgenic Mice in Pharmaceutical Development , 2010, Toxicologic pathology.
[142] J. Huff. Chemicals Studied and Evaluated in Long‐Term Carcinogenesis Bioassays by Both the Ramazzini Foundation and the National Toxicology Program , 2002, Annals of the New York Academy of Sciences.
[143] G. Williams,et al. Aspartame: A Safety Evaluation Based on Current Use Levels, Regulations, and Toxicological and Epidemiological Studies , 2007, Critical reviews in toxicology.
[144] T. Pastoor,et al. Historical perspective of the cancer bioassay. , 2005, Scandinavian journal of work, environment & health.
[145] Mark Fowler,et al. Food Safety Modernization Act , 2013 .
[146] S. Plassmann,et al. Successful Drug Development Despite Adverse Preclinical Findings Part 2: Examples , 2010, Journal of toxicologic pathology.
[147] Daniel Morton,et al. An Analysis of Pharmaceutical Experience with Decades of Rat Carcinogenicity Testing , 2011, Toxicologic pathology.
[148] G. Williams,et al. IFSTP guidelines for the design and interpretation of the chronic rodent carcinogenicity bioassay. , 1992, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[149] Robert A. Baan,et al. The Science and Practice of Carcinogen Identification and Evaluation , 2004, Environmental health perspectives.
[150] P. Nambiar,et al. The rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals , 2013, Toxicologic pathology.
[151] David Kirkland,et al. A core in vitro genotoxicity battery comprising the Ames test plus the in vitro micronucleus test is sufficient to detect rodent carcinogens and in vivo genotoxins. , 2011, Mutation research.
[152] R. Hoffman. In vitro sensitivity assays in cancer: A review, analysis, and prognosis , 1991, Journal of clinical laboratory analysis.
[153] Expectations for Transgenic Rodent Cancer Bioassay Models , 2001, Toxicologic pathology.
[154] J. P. Van Oosterhout,et al. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. , 1997, Regulatory toxicology and pharmacology : RTP.
[155] J. Butel,et al. The history of tumor virology. , 2008, Cancer research.
[156] Dawn G Goodman,et al. Best Practices Guideline: Toxicologic Histopathology , 2004, Toxicologic pathology.
[157] Christopher Portier,et al. Human carcinogenic risk evaluation, Part V: The national toxicology program vision for assessing the human carcinogenic hazard of chemicals. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[158] Bas J Blaauboer,et al. An expert consortium review of the EC-commissioned report "alternative (Non-Animal) methods for cosmetics testing: current status and future prospects - 2010". , 2011, ALTEX.
[159] J. Haseman,et al. The role of transgenic mouse models in carcinogen identification. , 2002, Environmental health perspectives.
[160] Ocspp,et al. PRN 96-5: Interim Use of the Proposed Guidelines for Carcinogen Risk Assessment , 2014 .
[161] Draft OECD Guideline for the Testing of Chemicals , 2006 .
[162] C L Alden,et al. A Critical Review of the Effectiveness of Rodent Pharmaceutical Carcinogenesis Testing in Predicting for Human Risk , 2011, Veterinary pathology.
[163] Douglas C. Wolf,et al. Best Practices for Use of Historical Control Data of Proliferative Rodent Lesions , 2009, Toxicologic pathology.
[164] I C Munro,et al. Rodent carcinogenicity tests need be no longer than 18 months: an analysis based on 210 chemicals in the IARC monographs. , 2000, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[165] Paul L. Carmichael,et al. Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs , 2011, Mutagenesis.
[166] Samuel M Cohen,et al. Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[167] Fuart Gatnik Mojca,et al. Review of QSAR Models and Software Tools for Predicting of Genotoxicity and Carcinogenicity , 2010 .
[168] S. Cohen. An enhanced thirteen-week bioassay as an alternative for screening for carcinogenesis factors. , 2010, Asian Pacific journal of cancer prevention : APJCP.
[169] B. Ames,et al. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[170] J H Weisburger,et al. Carcinogen testing: current problems and new approaches. , 1981, Science.
[171] V. Strauss,et al. Best Practices for Clinical Pathology Testing in Carcinogenicity Studies , 2011, Toxicologic pathology.
[172] A. Goldberg,et al. Alternatives in toxicology , 2006 .
[173] R. Tennant,et al. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. , 1995, Environmental health perspectives.
[174] Jennifer Seed,et al. A Framework for Human Relevance Analysis of Information on Carcinogenic Modes of Action , 2003, Critical reviews in toxicology.
[175] J. D. de Camargo. Chemical carcinogenesis – mode of action to inform quantitative human risk , 2013, BMC Proceedings.
[176] E Spencer Williams,et al. The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH. , 2009, Regulatory toxicology and pharmacology : RTP.
[177] A. Jacobs,et al. History of Chronic Toxicity and Animal Carcinogenicity Studies for Pharmaceuticals , 2013, Veterinary pathology.
[178] J. Contrera,et al. Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. , 1997, Regulatory toxicology and pharmacology : RTP.
[179] Nicola J Hewitt,et al. International prevalidation studies of the EpiDerm 3D human reconstructed skin micronucleus (RSMN) assay: transferability and reproducibility. , 2010, Mutation research.
[180] L. Bernstein,et al. Target organs in chronic bioassays of 533 chemical carcinogens. , 1991, Environmental health perspectives.
[181] C. Capen,et al. Neoplastic Lesions of Questionable Significance to Humans , 1994, Toxicologic pathology.
[182] Albrecht Poth,et al. Bhas42 cell transformation assay as a predictor of carcinogenicity , 2008 .
[183] Romualdo Benigni,et al. Alternative strategies for carcinogenicity assessment: an efficient and simplified approach based on in vitro mutagenicity and cell transformation assays. , 2011, Mutagenesis.
[184] J. Heddle,et al. The production of micronuclei from chromosome aberrations in irradiated cultures of human lymphocytes. , 1976, Mutation research.
[185] J H Weisburger,et al. Systematic carcinogen testing through the decision point approach. , 1981, Annual review of pharmacology and toxicology.
[186] The National Library of Medicine and its role. , 1993 .
[187] M D Waters,et al. Short-term tests for defining mutagenic carcinogens. , 1999, IARC scientific publications.
[188] G. Jena,et al. Regulatory requirements and ICH guidelines on carcinogenicity testing of pharmaceuticals: A review on current status , 2005 .
[189] S. O’Rahilly,et al. PPARγ and human metabolic disease , 2006 .
[190] J. Lafitte,et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.
[191] Harald Enzmann,et al. Principles of Testing for Carcinogenic Activity , 2007 .